3 Engineering and Construction Major, Hospital Network and Pharma Company Stocks With a Strong Future Roadmap: Larsen & Toubro, Krishna Institute of Medical Sciences and Alkem Laboratories
- November 5, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Larsen & Toubro, Krishna Institute of Medical Sciences and Alkem Laboratories: ROE of 10.7% to 16.7% and FY22 to FY26 revenue CAGR of 9.1% to 23.8%. Prices as of 4 Nov 2026.
Quick Answer
The three engineering, hospital chain and pharma stocks to watch are Larsen & Toubro, Krishna Institute of Medical Sciences and Alkem Laboratories. Their return on equity ranges from 10.7% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 23.8%. Alkem Laboratories has the highest return on equity at 16.7%, while Krishna Institute of Medical Sciences has the fastest revenue growth at 23.8% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
Engineering, hospital chain and pharma stocks bring together companies with a visible plan for the years ahead. Larsen & Toubro, Krishna Institute of Medical Sciences and Alkem Laboratories cover an engineering and construction conglomerate, a multi speciality hospital network and a pharmaceutical company.
This list covers three engineering, hospital chain and pharma stocks with complete current figures: Larsen & Toubro, Krishna Institute of Medical Sciences and Alkem Laboratories. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Engineering, Hospital Chain and Pharma Stocks?
Engineering, hospital chain and pharma stocks are listed companies that build infrastructure, energy and defence projects, run multi-speciality hospitals in southern India, and sell branded generics, anti-infectives and other medicines. Their earnings depend on project awards, patient volumes and prescriptions.
Engineering, Hospital Chain and Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Larsen & Toubro | 3,944.4 | 501,514 | 25.6 | 21.9 | 14.7 | 1.15 |
| Krishna Institute of Medical Sciences | 740.55 | 28,495 | 146.5 | 59.6 | 10.7 | 1.89 |
| Alkem Laboratories | 5,216.5 | 59,723 | 27.1 | 36.0 | 16.7 | 0.15 |
On valuation, Alkem Laboratories trades at a P/E below the industry P/E, while Larsen & Toubro and Krishna Institute of Medical Sciences trade above it, which reflects the growth the market already expects. Readers comparing engineering, hospital chain and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in engineering, hospital chain and pharma stocks can use the coming numbers to test whether growth is holding.
Why Do Engineering, Hospital Chain and Pharma Stocks Have a Strong Roadmap in India?
Engineering, hospital chain and pharma stocks have a strong roadmap in India because large infrastructure pipelines, growing demand for advanced hospital care and steady medicine use keep widening the market for these companies.
- Engineering projects. Infrastructure and energy orders build up.
- Hospitals. Patients seek advanced care.
- Pharma. Branded medicines reach more patients.
Why Larsen & Toubro Features Among These Engineering, Hospital Chain and Pharma Stocks
Among the engineering, hospital chain and pharma stocks on this list, Larsen and Toubro is a Mumbai-based engineering and construction conglomerate that builds infrastructure, energy and defence projects and also runs technology services, financial services and electronics businesses.
Revenue rose from Rs 158,788 crore in FY22 to Rs 291,635 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 10,291 crore in FY22 to Rs 19,159 crore in FY26, which works out to a compound annual growth rate of 16.8%.
In the June 2026 quarter, revenue grew 8.1% year on year to Rs 70,318 crore, while net profit rose 15.2% to Rs 4,983 crore. The company has a return on equity of 14.7%, a debt to equity ratio of 1.15 and a market capitalisation of Rs 501,514 crore. The stock trades at a P/E of 25.6, above the industry P/E of 21.9.
Roadmap: The company has a very large order book across infrastructure, energy and hydrocarbon projects, supported by government capital spending. Its growing technology and green energy businesses widen its sources of growth.
What to watch: Monitor order inflows, project execution and government infrastructure spending.
Why Krishna Institute of Medical Sciences Features Among These Engineering, Hospital Chain and Pharma Stocks
Among the construction, health and drug shares on this list, Krishna Institute of Medical Sciences, known as KIMS Hospitals, runs a network of multi-specialty hospitals in Telangana, Andhra Pradesh and other states, with strengths in cardiac, neuro and transplant care.
In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%.
Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6.
Roadmap: The company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.
What to watch: Track bed additions, occupancy and revenue per occupied bed.
Why Alkem Laboratories Features Among These Engineering, Hospital Chain and Pharma Stocks
Among the three companies on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.
The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0.
Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore.
Roadmap: Alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
What to watch: Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.
Larsen & Toubro vs Krishna Institute of Medical Sciences vs Alkem Laboratories on Key Financials
The table below sets the three engineering, hospital chain and pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Larsen & Toubro | 158,788 | 291,635 | 16.4% | 19,159 | 6.6% |
| Krishna Institute of Medical Sciences | 1,671 | 3,931 | 23.8% | 242 | 6.2% |
| Alkem Laboratories | 10,797 | 15,296 | 9.1% | 2,353 | 15.4% |
Alkem Laboratories posts the highest return on equity in this group at 16.7%. Larsen & Toubro has the largest FY26 revenue at Rs 291,635 crore, and Krishna Institute of Medical Sciences shows the fastest revenue growth with a 23.8% compound annual rate. A useful habit with engineering, hospital chain and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Larsen & Toubro | 65,036 | 70,318 | 8.1% |
| Krishna Institute of Medical Sciences | 879 | 1,196 | 36.1% |
| Alkem Laboratories | 3,508 | 3,893 | 11.0% |
Key Risks to Check Before Investing in Engineering, Hospital Chain and Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these engineering, hospital chain and pharma stocks, the main points are: Long-term construction, health and drug shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Order timing. Project awards can shift between periods.
- Capacity ramp up. New hospitals take time to fill beds and reach full returns.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter engineering, hospital chain and pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Engineering, Hospital Chain and Pharma Stocks
Engineering, hospital chain and pharma stocks suit investors who prefer to study business strength before price moves. Larsen & Toubro, Krishna Institute of Medical Sciences and Alkem Laboratories each have a clear plan to grow. Based on the 4 November 2026 close, Larsen & Toubro trades at Rs 3,944.4, Krishna Institute of Medical Sciences at Rs 740.55 and Alkem Laboratories at Rs 5,216.5. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these engineering, hospital chain and pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track engineering, hospital chain and pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are engineering, hospital chain and pharma stocks?
Ans. Engineering, hospital chain and pharma stocks are listed companies that build infrastructure, energy and defence projects, run multi-speciality hospitals in southern India, and sell branded generics, anti-infectives and other medicines. Their earnings depend on project awards, patient volumes and prescriptions. This list looks at three of them, Larsen & Toubro, Krishna Institute of Medical Sciences and Alkem Laboratories, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which engineering, hospital chain and pharma stocks are covered in this list?
Ans. This list covers Larsen & Toubro, Krishna Institute of Medical Sciences and Alkem Laboratories. Based on the 4 November 2026 close, Larsen & Toubro traded at Rs 3,944.4, Krishna Institute of Medical Sciences at Rs 740.55 and Alkem Laboratories at Rs 5,216.5. Their return on equity ranges from 10.7% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 23.8%.
Why do engineering, hospital chain and pharma stocks have a strong future roadmap in India?
Ans. Engineering, hospital chain and pharma stocks have a strong roadmap in India because large infrastructure pipelines, growing demand for advanced hospital care and steady medicine use keep widening the market for these companies. The main drivers are as follows. Engineering projects. Infrastructure and energy orders build up. Hospitals. Patients seek advanced care. Pharma. Branded medicines reach more patients. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Larsen & Toubro performed financially?
Ans. Revenue rose from Rs 158,788 crore in FY22 to Rs 291,635 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 10,291 crore in FY22 to Rs 19,159 crore in FY26, which works out to a compound annual growth rate of 16.8%. In the June 2026 quarter, revenue grew 8.1% year on year to Rs 70,318 crore, while net profit rose 15.2% to Rs 4,983 crore. The company has a return on equity of 14.7%, a debt to equity ratio of 1.15 and a market capitalisation of Rs 501,514 crore. The stock trades at a P/E of 25.6, above the industry P/E of 21.9. Looking ahead, the company has a very large order book across infrastructure, energy and hydrocarbon projects, supported by government capital spending. Its growing technology and green energy businesses widen its sources of growth.
How has Krishna Institute of Medical Sciences performed financially?
Ans. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%. Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6. Looking ahead, the company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.
How has Alkem Laboratories performed financially?
Ans. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0. Looking ahead, alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
What risks should investors check before buying engineering, hospital chain and pharma stocks?
Ans. Investors should check a few risks before buying engineering, hospital chain and pharma stocks. Order timing. Project awards can shift between periods. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of engineering, hospital chain and pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
